CB8025-21845 entitled A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpa

Administered By

Contributors

Start/End

  • August 1, 2019 - July 31, 2021